Dynavax Technologies | DVAX - Equity Capital And Reserves


Dynavax Technologies reported $534.14M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Adma Biologics USD 431.19M 32.87M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
AstraZeneca USD 45.89B 1.17B Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Dynavax Technologies USD 534.14M 39.98M Sep/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
TG Therapeutics USD 607.22M 330.79M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025